Analyst Ratings for CRISPR Therapeutics (CRSP)
CRSP Rating Summary
CRSP Price Target Summary
- Highest: $268.00 (Brookline Capital Markets)
- Lowest: $6.00 (Baird)
- Average: $75.21
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$75.21 (+33.1%)
* Over Last 12-Mos
Rating Score: 5.6 / 10
Percentile Rank: 59%
Avg. $ Target:
$75.21 (+33.1%)
* Over Last 12-Mos
Rating Score: 5.6 / 10
Percentile Rank: 59%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/18/2025 | JPMorgan | Brian Cheng | New Coverage | Overweight (N/A) |
70.00 (N/A) |
61.19 (56.50) |
-7.66% | Details |
| 8/25/2025 | Evercore ISI » Updated 2/13/2026 |
Liisa Bayko | New Coverage | Outperform (N/A) |
74.00 (62.00) |
54.32 (56.50) |
4.01% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
